CellCentric Secures $220M to Accelerate Myeloma Drug Inobrodib
May 11, 2026, 9:36 pm
CellCentric secured $220 million in Series D funding. This capital fuels pivotal clinical trials for inobrodib. Inobrodib is a novel oral p300/CBP inhibitor. It targets relapsed or refractory multiple myeloma. Phase 2 data demonstrated significant efficacy. It showed a twofold increase in response rates. This was in heavily pretreated patients. The investment supports global Phase 3 studies. It also expands combination treatment strategies. Inobrodib offers a new, orally administered option. It addresses a critical unmet need for myeloma patients. FDA Fast Track designation confirms its importance.
CellCentric made headlines. The biotechnology company announced a massive funding round. It secured an oversubscribed $220 million in Series D financing. This capital infusion is significant. It directly supports the rapid advancement of inobrodib. Inobrodib is CellCentric's lead drug candidate. It targets multiple myeloma patients. This investment marks a pivotal moment for the company. It validates the drug's potential.
Venrock Healthcare Capital Partners led the financing. Other top-tier investors joined. Fidelity Management & Research Company, Sofinnova Partners, and HBM Healthcare participated. Existing investors also reaffirmed their commitment. These included RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and American Cancer Society BrightEdge. Such broad investor support signals strong confidence. It highlights the perceived value of inobrodib.
The funds have a clear purpose. They will accelerate inobrodib's clinical development. Enrollment continues for the Phase 2 DOMMINO-1 study. This trial operates in the UK and US. A global Phase 3 DOMMINO-2 trial is also planned. Its initiation is set for the second half of 2026. This expansion underscores CellCentric's global ambitions. It aims to bring this novel therapy to patients worldwide.
Inobrodib represents a new therapeutic modality. It is a first-in-class oral p300/CBP inhibitor. This mechanism of action is unique. It offers a fresh approach to treating cancer. Specifically, it targets the histone acetyltransferase p300/CBP. This enzyme plays a crucial role in gene regulation. Its inhibition can disrupt cancer cell growth.
Multiple myeloma remains a challenging blood cancer. Patients often develop resistance to existing therapies. Especially those with relapsed or refractory multiple myeloma (RRMM). These patients have few remaining options. A critical unmet need exists. This is particularly true after bispecific T cell engager or anti-BCMA therapies fail. Inobrodib aims to fill this void.
Clinical data shows promise. Phase 2 dose-optimization results were presented. This occurred at the American Society of Hematology (ASH) meeting in December 2025. The data highlighted inobrodib's efficacy. A 20 mg dose was combined with pomalidomide and dexamethasone (InoPd). This triplet regimen demonstrated strong responses.
The results were impressive. InoPd achieved at least a twofold increase in response rates. This was compared to historical alternative therapies. The patient population was heavily pretreated. Many had received a median of five prior lines of therapy. This indicates robust activity in difficult-to-treat cases. The drug also showed a manageable safety profile. Consistency of clinical activity stood out.
The oral administration of inobrodib offers a significant advantage. It allows for at-home use. Patients avoid intensive hospital visits. This convenience improves quality of life. It reduces the burden of treatment. This aspect is vital for chronically ill patients. An oral drug with a novel, additive approach could transform care.
CellCentric plans to explore inobrodib broadly. Beyond InoPd, combination strategies are underway. Inobrodib is being evaluated with bispecific therapies. These include elranatamab and teclistamab. This expands its potential utility. Proof of concept in a maintenance setting is also being explored. This could offer long-term disease control.
Regulatory bodies have recognized inobrodib's potential. The FDA previously granted Fast Track designation. This expedites the development and review of promising new drugs. It signals the agency's belief in the therapy's impact. Inobrodib also received orphan drug designation for RRMM. This supports drugs for rare diseases. These designations underscore the urgent need for new myeloma treatments.
CellCentric maintains full control over inobrodib. It holds all development and commercial rights. This strategic position allows flexibility. The company can expand its program. It can pursue various combination therapies. This autonomy is crucial for long-term growth.
CellCentric operates as a transatlantic business. Its roots are in Cambridge, UK. It also maintains offices in Boston, USA. This dual presence fosters innovation. It connects leading research hubs. The company's focus remains clear: delivering transformative treatments.
The $220 million financing propels CellCentric forward. It positions the company strongly. Pivotal studies are now fully funded. Inobrodib has the potential to redefine multiple myeloma treatment. It offers a new, convenient, and effective option. This could profoundly impact patient lives. The future of myeloma therapy looks brighter.
CellCentric made headlines. The biotechnology company announced a massive funding round. It secured an oversubscribed $220 million in Series D financing. This capital infusion is significant. It directly supports the rapid advancement of inobrodib. Inobrodib is CellCentric's lead drug candidate. It targets multiple myeloma patients. This investment marks a pivotal moment for the company. It validates the drug's potential.
Venrock Healthcare Capital Partners led the financing. Other top-tier investors joined. Fidelity Management & Research Company, Sofinnova Partners, and HBM Healthcare participated. Existing investors also reaffirmed their commitment. These included RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and American Cancer Society BrightEdge. Such broad investor support signals strong confidence. It highlights the perceived value of inobrodib.
The funds have a clear purpose. They will accelerate inobrodib's clinical development. Enrollment continues for the Phase 2 DOMMINO-1 study. This trial operates in the UK and US. A global Phase 3 DOMMINO-2 trial is also planned. Its initiation is set for the second half of 2026. This expansion underscores CellCentric's global ambitions. It aims to bring this novel therapy to patients worldwide.
Inobrodib represents a new therapeutic modality. It is a first-in-class oral p300/CBP inhibitor. This mechanism of action is unique. It offers a fresh approach to treating cancer. Specifically, it targets the histone acetyltransferase p300/CBP. This enzyme plays a crucial role in gene regulation. Its inhibition can disrupt cancer cell growth.
Multiple myeloma remains a challenging blood cancer. Patients often develop resistance to existing therapies. Especially those with relapsed or refractory multiple myeloma (RRMM). These patients have few remaining options. A critical unmet need exists. This is particularly true after bispecific T cell engager or anti-BCMA therapies fail. Inobrodib aims to fill this void.
Clinical data shows promise. Phase 2 dose-optimization results were presented. This occurred at the American Society of Hematology (ASH) meeting in December 2025. The data highlighted inobrodib's efficacy. A 20 mg dose was combined with pomalidomide and dexamethasone (InoPd). This triplet regimen demonstrated strong responses.
The results were impressive. InoPd achieved at least a twofold increase in response rates. This was compared to historical alternative therapies. The patient population was heavily pretreated. Many had received a median of five prior lines of therapy. This indicates robust activity in difficult-to-treat cases. The drug also showed a manageable safety profile. Consistency of clinical activity stood out.
The oral administration of inobrodib offers a significant advantage. It allows for at-home use. Patients avoid intensive hospital visits. This convenience improves quality of life. It reduces the burden of treatment. This aspect is vital for chronically ill patients. An oral drug with a novel, additive approach could transform care.
CellCentric plans to explore inobrodib broadly. Beyond InoPd, combination strategies are underway. Inobrodib is being evaluated with bispecific therapies. These include elranatamab and teclistamab. This expands its potential utility. Proof of concept in a maintenance setting is also being explored. This could offer long-term disease control.
Regulatory bodies have recognized inobrodib's potential. The FDA previously granted Fast Track designation. This expedites the development and review of promising new drugs. It signals the agency's belief in the therapy's impact. Inobrodib also received orphan drug designation for RRMM. This supports drugs for rare diseases. These designations underscore the urgent need for new myeloma treatments.
CellCentric maintains full control over inobrodib. It holds all development and commercial rights. This strategic position allows flexibility. The company can expand its program. It can pursue various combination therapies. This autonomy is crucial for long-term growth.
CellCentric operates as a transatlantic business. Its roots are in Cambridge, UK. It also maintains offices in Boston, USA. This dual presence fosters innovation. It connects leading research hubs. The company's focus remains clear: delivering transformative treatments.
The $220 million financing propels CellCentric forward. It positions the company strongly. Pivotal studies are now fully funded. Inobrodib has the potential to redefine multiple myeloma treatment. It offers a new, convenient, and effective option. This could profoundly impact patient lives. The future of myeloma therapy looks brighter.